These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 10471608)

  • 1. Impact of immunomodulating therapy on morbidity in patients with severe sepsis.
    Pittet D; Harbarth S; Suter PM; Reinhart K; Leighton A; Barker C; Macdonald F; Abraham E
    Am J Respir Crit Care Med; 1999 Sep; 160(3):852-7. PubMed ID: 10471608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p55 Tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. Ro 45-2081 Study Group.
    Abraham E; Glauser MP; Butler T; Garbino J; Gelmont D; Laterre PF; Kudsk K; Bruining HA; Otto C; Tobin E; Zwingelstein C; Lesslauer W; Leighton A
    JAMA; 1997 May; 277(19):1531-8. PubMed ID: 9153367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lenercept (p55 tumor necrosis factor receptor fusion protein) in severe sepsis and early septic shock: a randomized, double-blind, placebo-controlled, multicenter phase III trial with 1,342 patients.
    Abraham E; Laterre PF; Garbino J; Pingleton S; Butler T; Dugernier T; Margolis B; Kudsk K; Zimmerli W; Anderson P; Reynaert M; Lew D; Lesslauer W; Passe S; Cooper P; Burdeska A; Modi M; Leighton A; Salgo M; Van der Auwera P;
    Crit Care Med; 2001 Mar; 29(3):503-10. PubMed ID: 11373411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-inflammatory response after infusion of p55 soluble tumor necrosis factor receptor fusion protein for severe sepsis.
    Butty VL; Roux-Lombard P; Garbino J; Dayer JM; Ricou B;
    Eur Cytokine Netw; 2003; 14(1):15-9. PubMed ID: 12799209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.
    Abraham E; Wunderink R; Silverman H; Perl TM; Nasraway S; Levy H; Bone R; Wenzel RP; Balk R; Allred R
    JAMA; 1995 Mar 22-29; 273(12):934-41. PubMed ID: 7884952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group.
    Neurology; 1999 Aug; 53(3):457-65. PubMed ID: 10449104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.
    Harbarth S; Garbino J; Pugin J; Romand JA; Lew D; Pittet D
    Am J Med; 2003 Nov; 115(7):529-35. PubMed ID: 14599631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group.
    Fisher CJ; Agosti JM; Opal SM; Lowry SF; Balk RA; Sadoff JC; Abraham E; Schein RM; Benjamin E
    N Engl J Med; 1996 Jun; 334(26):1697-702. PubMed ID: 8637514
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis of 314 episodes of sepsis in medical intensive care unit in university hospital: impact of intensive care unit performance and antimicrobial therapy.
    Degoricija V; Sharma M; Legac A; Gradiser M; Sefer S; Vucicević Z
    Croat Med J; 2006 Jun; 47(3):385-97. PubMed ID: 16758516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Importance of underlying mechanism and genotype on outcome of sepsis trials.
    McIntyre L; Walley KR
    Crit Care Med; 2001 Mar; 29(3):677-9. PubMed ID: 11373447
    [No Abstract]   [Full Text] [Related]  

  • 11. Early administration of high-dose antithrombin in severe sepsis: single center results from the KyberSept-trial.
    Eid A; Wiedermann CJ; Kinasewitz GT
    Anesth Analg; 2008 Nov; 107(5):1633-8. PubMed ID: 18931224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein, Ro 45-2081 (lenercept): results of a dose-finding study in rheumatoid arthritis.
    Furst DE; Weisman M; Paulus HE; Bulpitt K; Weinblatt M; Polisson R; Zaug M; Kneer J; Van der Auwera P; Stevens RM
    J Rheumatol; 2003 Oct; 30(10):2123-6. PubMed ID: 14528504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Release of tumor necrosis factor alpha and its soluble receptor p55 in clinical septic syndrome.
    Modzelewski B
    Arch Immunol Ther Exp (Warsz); 1997; 45(2-3):213-9. PubMed ID: 9597089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal tumor necrosis factor receptor binding protein: optimum biological activity of a truncated p55 soluble tumor necrosis factor receptor-IgG fusion protein.
    Corcoran AE; Scallon BJ; Trinh H; Chernajovsky Y; Ghrayeb J; Feldmann M
    Eur Cytokine Netw; 1998 Sep; 9(3):255-62. PubMed ID: 9831174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic and organ dysfunction response during infusion of recombinant human activated protein C (rhAPC) in severe sepsis and septic shock.
    Gullo A; Iscra F; Di Capua G; Berlot G; Lucangelo U; Peratoner A; Fasiolo S; Viviani M; Consales C; Zicari A
    Minerva Anestesiol; 2005 Dec; 71(12):785-801. PubMed ID: 16288186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis.
    Rau R; Sander O; van Riel P; van de Putte L; Hasler F; Zaug M; Kneer J; van der Auwera P; Stevens RM;
    J Rheumatol; 2003 Apr; 30(4):680-90. PubMed ID: 12672184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical trial.
    Krueger WA; Lenhart FP; Neeser G; Ruckdeschel G; Schreckhase H; Eissner HJ; Forst H; Eckart J; Peter K; Unertl KE
    Am J Respir Crit Care Med; 2002 Oct; 166(8):1029-37. PubMed ID: 12379544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. USAN Council. List No.407. New names. Lenercept.
    Clin Pharmacol Ther; 1998 Aug; 64(2):234. PubMed ID: 9758530
    [No Abstract]   [Full Text] [Related]  

  • 19. Antithrombin III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin III in severe sepsis.
    Eisele B; Lamy M; Thijs LG; Keinecke HO; Schuster HP; Matthias FR; Fourrier F; Heinrichs H; Delvos U
    Intensive Care Med; 1998 Jul; 24(7):663-72. PubMed ID: 9722035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group.
    Abraham E; Anzueto A; Gutierrez G; Tessler S; San Pedro G; Wunderink R; Dal Nogare A; Nasraway S; Berman S; Cooney R; Levy H; Baughman R; Rumbak M; Light RB; Poole L; Allred R; Constant J; Pennington J; Porter S
    Lancet; 1998 Mar; 351(9107):929-33. PubMed ID: 9734938
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.